MD, Stanford University School of Medicine
DPH/DrPH, Harvard School of Public Health
MPH, Harvard School of Public Health
AB, Harvard College

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Hicks B, Kaye JA, Azoulay L, Kristensen KB, Habel LA, Pottegård A. The application of lag times in cancer pharmacoepidemiology: a narrative review. Ann Epidemiol. 2023 Aug; 84:25-32. PMID: 37169040
  2. Bhandari NR, Hess LM, Parikh RC, Sireci AN, Krein PM, Kaye JA. Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the USA. Per Med. 2023 Mar; 20(2):131-142. PMID: 36749615
  3. Johannes CB, Saltus CW, Kaye JA, Calingaert B, Kaplan S, Gordon MF, Andrews EB. The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database. Pharmacoepidemiol Drug Saf. 2022 Jun; 31(6):643-651. PMID: 35224798; PMCID: PMC9321028; DOI: 10.1002/pds.5422;
  4. Parikh R, Hess LM, Esterberg E, Bhandari NR, Kaye JA. Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer. Thyroid Res. 2022 Feb 12; 15(1):2. PMID: 35151352; PMCID: PMC8840546; DOI: 10.1186/s13044-021-00119-9;
  5. Fortuny J, Plana E, Kaye JA. Serum lipid trajectories in the years before a lymphoma diagnosis. Leuk Lymphoma. 2022 02; 63(2):291-303. PMID: 34963420
  6. Arana A, Pottegård A, Kuiper JG, Booth H, Reutfors J, Calingaert B, Lund LC, Crellin E, Schmitt-Egenolf M, Kaye JA, Gembert K, Rothman KJ, Kieler H, Dedman D, Houben E, Gutiérrez L, Hallas J, Perez-Gutthann S. Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clin Epidemiol. 2021; 13:1141-1153.View Related Profiles. PMID: 35002327; PMCID: PMC8721027; DOI: 10.2147/CLEP.S331287;
  7. Boeri M, Purdum AG, Sutphin J, Hauber B, Kaye JA. CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion. Future Oncol. 2021 Dec; 17(34):4697-4709. PMID: 34581197
  8. Goyal RK, Jain P, Nagar SP, Le H, Kabadi SM, Davis K, Kaye JA, Du XL, Wang M. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leuk Lymphoma. 2021 06; 62(6):1325-1334. PMID: 33966583
  9. Goyal RK, Nagar SP, Kabadi SM, Le H, Davis KL, Kaye JA. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population. Cancer Med. 2021 04; 10(8):2690-2702. PMID: 33734606; PMCID: PMC8026937; DOI: 10.1002/cam4.3855;
  10. Richardson D, Zhan L, Mahtani R, McRoy L, Mitra D, Reynolds M, Odom D, Hollis K, Kaye JA, Jones C, Hargis J. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application. Breast Cancer Res Treat. 2021 May; 187(1):113-124. PMID: 33428072; PMCID: PMC8062359; DOI: 10.1007/s10549-020-06082-7;
Showing 10 of 124 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Contact for Mentoring: